Correlates of acute renal failure in patients receiving parenteral amphotericin B
Authors:
- David W. BatesDBDavid W. Bates
- Ling SuLSLing Su
- Donghui T. YuDYDonghui T. Yu
- Glenn M. ChertowGCGlenn M. Chertow
- Diane L. SegerDSDiane L. Seger
- Daniel R.J. GomesDGDaniel R.J. Gomes
- Richard PlattRPRichard Platt
- 1 October 2001
- journal article
- Published by Elsevier in Kidney International
- Vol. 60 (4) , 1452-1459
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- Risk factors for amphotericin B- induced nephrotoxicityJournal of Antimicrobial Chemotherapy, 1999
- AmBisome (Liposomal Amphotericin B): A Comparative ReviewThe Journal of Clinical Pharmacology, 1998
- Amphotericin B Use in a Community Hospital, with Special Emphasis on Side EffectsClinical Infectious Diseases, 1998
- Liposomal Amphotericin BDrugs, 1998
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- Risk factors for amphotericin B-associated nephrotoxicityThe American Journal of Medicine, 1989
- Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients.Journal of Clinical Pathology, 1988
- Nephrotoxic effects of amphotericin B, including renal tubular acidosisThe American Journal of Medicine, 1969
- Renal Tubular Acidosis Due to Amphotericin BNew England Journal of Medicine, 1968